No Data
Enwei Pharmaceutical (301331.SZ): Henan's first batch of key varieties, including heat-clearing and detoxifying oral liquid, antiviral oral liquid, and other products, has been mass-produced and is now fully available for sale.
On January 8, Gelonghui reported that Enwei Pharmaceutical (301331.SZ) stated on the investor interaction platform that the company's products including Compound Paracetamol and Amantadine Tablets, Compound Silver Qiao Amine Capsules, and Children's Paracetamol and Yellow Nasal Capsules are suitable for relieving symptoms of common and epidemic influenza. Children's Cough and Wheezing Granules have functions of promoting lung function, clearing heat, stopping cough, and expelling phlegm. The products are mainly sold through offline OTC and online e-commerce channels. The company's key products from Henan, including Heat-clearing and Detoxifying Oral Liquid, Anti-Viral Oral Liquid, etc., have been mass-produced and are fully available for sale.
Enwei Pharmaceuticals (301331.SZ): The design plan for the product packaging of An Gong Niu Huang Wan has been completed and is preparing for the procurement of related raw materials.
On December 23, Glonghui reported that Enwei Pharmaceutical (301331.SZ) stated on the investor interaction platform that the company's Henan Xinxin Pharmaceutical variety "Angong Niuhuang Wan" has completed the product packaging design plan and is in the process of preparing for raw material procurement; "Wuji Bailing Wan" is one of the products the company will focus on in the next step, and discussions with potential partners and agents for this product are currently underway; subsequent batches of commissioned production will also begin gradually, including varieties such as Jian'er pill, Ganmao Shu granule, Yilun Jianpi granule, Xiaoer Magan granule, Banlan Gen granule, Yangxue Anshen tablet, Yaotong tablet, Ginseng Yangrong paste, and Yangyin Qingfei paste.
Earnings Troubles May Signal Larger Issues for Enwei Pharmaceutical (SZSE:301331) Shareholders
Enwei Pharmaceuticals: Report for the third quarter of 2024
Enwei Pharmaceutical (301331.SZ) released its performance for the first three quarters, with a net income of 22.02 million yuan, a year-on-year decrease of 69.81%.
Enwei Medicine (301331.SZ) disclosed the third quarter report of 2024, achieving revenue of 5....
Enwei Pharmaceuticals (301331.SZ) has accumulated repurchased 3.0258% of its shares, costing 0.102 billion yuan.
Announcement from Enwei Pharmaceutical (301331.SZ), the company traded through centralized bidding as of September 30, 2024...
Enwei Pharmaceutical Co., Ltd. (SZSE:301331) Stock's On A Decline: Are Poor Fundamentals The Cause?
